Brian Lenz Net Worth

The estimated Net Worth of Brian Lenz is at least $28 Million dollars as of 15 August 2023. Mr. Lenz owns over 809,262 units of Adma Biologics Inc stock worth over $26,908,460 and over the last 15 years he sold ADMA stock worth over $0. In addition, he makes $1,122,150 as Chief Financial Officer und Executive Vice President at Adma Biologics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Lenz ADMA stock SEC Form 4 insiders trading

Brian has made over 19 trades of the Adma Biologics Inc stock since 2010, according to the Form 4 filled with the SEC. Most recently he exercised 809,262 units of ADMA stock worth $2,516,805 on 15 August 2023.

The largest trade he's ever made was exercising 809,262 units of Adma Biologics Inc stock on 15 August 2023 worth over $2,516,805. On average, Brian trades about 19,115 units every 101 days since 2010. As of 15 August 2023 he still owns at least 1,591,275 units of Adma Biologics Inc stock.

You can see the complete history of Mr. Lenz stock trades at the bottom of the page.

Brian Lenz biography

Brian Lenz serves as Chief Financial Officer, Executive Vice President of the Company. Mr. Lenz joined the Company as Vice President and Chief Financial Officer in May 2012. Mr. Lenz was previously employed by CorMedix Inc., a developmental-stage pharmaceutical and medical device company, where he held the position of Chief Financial Officer from February 2010 and Chief Operating Officer and Chief Financial Officer from January 2012 to May 2012. Prior to joining CorMedix, Mr. Lenz was Chief Financial Officer of Arno Therapeutics from July 2008 to February 2010, Chief Financial Officer of VioQuest Pharmaceuticals from April 2004 to June 2008, Controller of Chiral Quest, Inc., a subsidiary of VioQuest Pharmaceuticals, from October 2003 to March 2004, Controller of Smiths Detection from July 2000 to October 2003, and senior auditor at KPMG LLP from October 1998 to July 2000. Mr. Lenz received a B.S. from Rider University; an M.B.A. from Saint Joseph’s University and is a licensed Certified Public Accountant.Mr. Lenz joined the Company as Vice President and Chief Financial Officer in May 2012 and, in June 2018, became the Company’s Executive Vice President and Chief Financial Officer. Mr. Lenz was previously employed by CorMedix Inc., a developmental-stage pharmaceutical and medical device company, where he held the position of Chief Financial Officer from February 2010 and Chief Operating Officer and Chief Financial Officer from January 2012 to May 2012. Prior to joining CorMedix, Mr. Lenz was Chief Financial Officer of Arno Therapeutics from July 2008 to February 2010, Chief Financial Officer of VioQuest Pharmaceuticals from April 2004 to June 2008, Controller of Chiral Quest, Inc., a subsidiary of VioQuest Pharmaceuticals, from October 2003 to March 2004, Controller of Smiths Detection from July 2000 to October 2003, and senior auditor at KPMG LLP from October 1998 to July 2000. Mr. Lenz received a B.S. from Rider University, an M.B.A. from Saint Joseph’s University and is a licensed Certified Public Accountan

What is the salary of Brian Lenz?

As the Chief Financial Officer und Executive Vice President of Adma Biologics Inc, the total compensation of Brian Lenz at Adma Biologics Inc is $1,122,150. There are 3 executives at Adma Biologics Inc getting paid more, with Adam Grossman having the highest compensation of $1,702,020.

How old is Brian Lenz?

Brian Lenz is 47, he's been the Chief Financial Officer und Executive Vice President of Adma Biologics Inc since 2018. There are 9 older and 2 younger executives at Adma Biologics Inc. The oldest executive at Adma Biologics Inc is Dr. James Mond, 74, who is the Exec. VP, Chief Scientific Officer & Chief Medical Officer.

What's Brian Lenz's mailing address?

Brian's mailing address filed with the SEC is C/O ADMA BIOLOGICS, INC., 465 STATE ROUTE 17, RAMSEY, NJ, 07446.

Insiders trading at Adma Biologics Inc

Over the last 11 years, insiders at Adma Biologics Inc have traded over $43,950,328 worth of Adma Biologics Inc stock and bought 17,510,201 units worth $56,736,742 . The most active insiders traders include Advisors Llcperceptive Life..., Ag Biotest Pharmaceuticals ... und Divestiture Trust Biotest. On average, Adma Biologics Inc executives and independent directors trade stock every 34 days with the average trade being worth of $7,366,858. The most recent stock trade was executed by Lawrence P. Guiheen on 9 September 2024, trading 9,000 units of ADMA stock currently worth $97,200.

What does Adma Biologics Inc do?

adma is a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of primary immune deficiency disease (pidd) and certain infectious diseases. adma's mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases. the target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease, or who may be immune-compromised for medical reasons. adma’s lead product candidate, ri-002, has completed a phase iii clinical trial in patients with pidd and has met the primary endpoint. a bla for ri-002 was accepted by the fda on september 18, 2015. the company has received u.s. patent 9,107,906. for more information, please visit the company's website at www.admabiologics.com.

Complete history of Mr. Lenz stock trades at Adma Biologics Inc und CorMedix Inc

Adma Biologics Inc executives and stock owners

Adma Biologics Inc executives and other stock owners filed with the SEC include:

• Adam Grossman,
  President, Chief Executive Officer, Co-Founder, Director
• James Mond,
  Executive Vice President, Chief Scientific Officer, Chief Medical Officer
• Adam S. Grossman,
  Co-Founder, Pres, CEO & Director
• Brian Lenz,
  Chief Financial Officer, Executive Vice President
• Dr. James Mond,
  Exec. VP, Chief Scientific Officer & Chief Medical Officer
• Brian Lenz CPA, CPA,
  Exec. VP, CFO & GM of ADMA BioCenters
• Jerrold Grossman,
  Vice Chairman of the Board, Co-Founder
• Steven Elms,
  Independent Chairman of the Board
• Bryant Fong,
  Independent Director
• Lawrence Guiheen,
  Independent Director
• Dr. Jerrold B. Grossman D.P.S., Ph.D.,
  Co-Founder & Vice Chairman
• Dr. Jerrold B. Grossman Ph.D., D.P.S.,
  Co-Founder & Vice Chairman
• Martha Demski,
  Independent Director
• Cyndi Tolman,
  Sr. VP of Plasma Services
• Neal C. Fitzpatrick,
  VP of Sales
• Michael Goldstein,
  Sr. Director & Gen. Counsel
• Dr. Gene A. Wetzstein BCOP, Pharm.D.,
  Exec. Director & Head of Scientific Engagement
• Drew Pantello,
  VP of Marketing & Corp. Devel.
• Michael Least,
  VP of Sales & Commercial Operations
• Kaitlin Kestenberg,
  VP of Compliance, Project Management & Clinical Operations
• Skyler Bloom,
  Director of Investor Relations & Corp. Strategy
• Kim Tripodo,
  Exec. Director & Head of Human Resource and Admin. Operations
• Eric I Richman,
  Director
• Dov A Md Goldstein,
  Director
• Ag Biotest Pharmaceuticals ...,
  
• Young Kwon,
  
• Alison Cecily Finger,
  
• Divestiture Trust Biotest,
  10% owner
• Steve Elms,
  
• Advisors Llcperceptive Life...,
  
• Brad L. Tade,
  CFO and Treasurer
• Kaitlin M. Kestenberg Messina,
  COO and SVP, Compliance